Paysign Förvaltning
Förvaltning kriterier kontrolleras 3/4
Paysign VD är Mark Newcomer, utsedd i Mar 2006, har en mandatperiod på 20.33 år. totala årliga ersättningen är $ 2.75M, bestående av 38.1% lön 61.9% bonusar, inklusive företagsaktier och optioner. äger direkt 16.59% av företagets aktier, värda $ 79.00M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 5.4 år respektive 8.2 år.
Viktig information
Mark Newcomer
Verkställande direktör
US$2.8m
Total ersättning
| VD-lön i procent | 38.12% |
| Anställning som VD | 20.3yrs |
| Ägande av VD | 16.6% |
| Ledningens genomsnittliga anställningstid | 5.4yrs |
| Styrelsens genomsnittliga mandatperiod | 8.2yrs |
Senaste uppdateringar av ledningen
Recent updates
Uppdatering av berättelse • Jun 24
PAYS: 2026 Earnings Guidance And Margin Outlook Will Support Repricing
Analysts have maintained their $12.75 price target on Paysign, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E, which together support keeping the current valuation view unchanged. What’s in the News for Paysign Paysign issued earnings guidance for the second quarter of 2026, with expected revenue in a range of US$26.2 million to US$26.7 million.Uppdatering av berättelse • Jun 04
PAYS: Higher 2026 Margin Guidance And P/E Framework Will Support Repricing
Analysts have increased their price target on Paysign by $1 to $12.75, reflecting updated views on its growth, margins, and P/E assumptions. What's in the News Paysign issued earnings guidance for the first quarter of 2026, expecting revenue of US$27.0 million to US$27.5 million, with 137 active patient affordability programs and 589 plasma centers projected at quarter end.Uppdatering av berättelse • May 20
PAYS: Higher Margin Guidance And Premium P/E Framework Will Drive Repricing
Analysts have nudged their fair value estimate for Paysign up from $12.00 to $12.75, citing updated assumptions around growth, margins, and future P/E that fed into the latest price target increase highlighted in recent Street research. Analyst Commentary Recent Street research highlights a more constructive tone around Paysign, with bullish analysts pointing to the refreshed fair value estimate and updated assumptions as key supports for their views.Uppdatering av berättelse • Apr 30
PAYS: Higher Margin Outlook Will Support Repricing On Updated Profitability Assumptions
Analysts have raised their price target on Paysign by $1 to $12, citing updated assumptions around growth, profitability, discount rate and future P/E as the main drivers of this change. Analyst Commentary Bullish analysts are highlighting the recent price target move to US$12 as a sign of growing confidence in Paysign's outlook, with updated assumptions around growth, profitability, discount rate and future P/E at the core of their thesis.Uppdatering av berättelse • Apr 12
PAYS: Higher Margin Outlook And Raised P/E Assumption Will Support Repricing
Analysts lifted their Paysign price target by $1 to reflect slightly higher modeled revenue growth, modestly stronger profit margins, and an adjusted future P/E assumption, all under broadly consistent fair value and discount rate inputs. Analyst Commentary Bullish analysts framing the recent price target move highlight that the updated P/E assumption and slightly higher modeled revenue and margins support a higher fair value range for Paysign, while keeping discount rate inputs broadly consistent.Uppdatering av berättelse • Mar 28
PAYS: Higher Profit Margin Outlook Will Support More Constructive Share Repricing
The analyst price target for Paysign has increased from $9.50 to $12.00, with analysts citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as key drivers of the change. Analyst Commentary Recent research points to a more constructive view on Paysign, with bullish analysts updating their models to reflect what they see as improved fair value assumptions and a more supportive outlook for key valuation inputs such as discount rate, revenue growth, profit margin and future P/E.Analysartikel • Feb 05
The Price Is Right For Paysign, Inc. (NASDAQ:PAYS) Even After Diving 27%
Paysign, Inc. ( NASDAQ:PAYS ) shareholders that were waiting for something to happen have been dealt a blow with a 27...Analysartikel • Nov 16
Paysign, Inc. Just Beat EPS By 100%: Here's What Analysts Think Will Happen Next
Paysign, Inc. ( NASDAQ:PAYS ) just released its quarterly report and things are looking bullish. The company beat...Seeking Alpha • Oct 01
Paysign: Gaining Traction In The Patient Affordability Space Into 2026 (Hold)
Summary Paysign posted strong Q2 2025 results, with 33% YoY revenue growth and robust Pharma segment momentum, driven by US tariffs and new client wins. PAYS is rated a hold, as the stock trades at fair value ($5.83), despite expected high demand for co-payment cards and expanded patient affordability programs. Pharma segment revenue surged 189% YoY, offsetting a 4.7% YoY decline in the core Plasma segment, which faces ongoing headwinds from transitioning centers. While PAYS benefits from industry tailwinds and guidance consistency, risks remain due to Plasma's weakness and Pharma revenues still lagging Plasma's overall contribution. Read the full article on Seeking AlphaAnalysartikel • Aug 09
Paysign, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NasdaqCM:PAYS 1 Year Share Price vs Fair Value Explore Paysign's Fair Values from the Community and select yours One of...
Uppdatering av berättelse • Aug 07
Digital Payment Solutions Will Expand Healthcare Access Further
Analysts maintain a positive outlook on Paysign due to ongoing growth in its Patient Affordability segment, confidence in its pharmaceutical pipeline, and scalable model, resulting in no change to the consensus price target, which remains at $9.10. Analyst Commentary Bullish analysts highlight a strong outlook for Paysign's Patient Affordability segment, especially within the pharmaceutical industry.Analysartikel • May 06
Paysign, Inc.'s (NASDAQ:PAYS) 28% Price Boost Is Out Of Tune With Earnings
Those holding Paysign, Inc. ( NASDAQ:PAYS ) shares would be relieved that the share price has rebounded 28% in the last...Analysartikel • Mar 04
Paysign, Inc.'s (NASDAQ:PAYS) Share Price Not Quite Adding Up
With a median price-to-earnings (or "P/E") ratio of close to 18x in the United States, you could be forgiven for...Analysartikel • Dec 27
Here's Why Paysign (NASDAQ:PAYS) Has Caught The Eye Of Investors
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Seeking Alpha • Nov 20
Paysign Is A Leader In Fintech Healthcare Payments With Durable Profitable Growth
Summary Paysign is a promising microcap payment processing company with a projected 42% annualized return, potentially reaching $19/share by 2030 from $3.30/share today. The company excels in two primary sectors: plasma payment processing and pharma patient affordability, both offering significant growth and high gross margins. PAYS's plasma business boasts a 40% market share with steady 10-15% annual growth, while the pharma segment is expected to surpass plasma with rapid expansion. Risks include increased competition, potential loss of key customers, and limited financial resources, but catalysts like market share gains and acquisition potential bolster the investment thesis. Read the full article on Seeking Alpha
Ny berättelse • Sep 26
Rapid Growth In Patient Affordability Market Fuels Optimism Despite Looming Margin Pressures
The expansion into the patient affordability segment and significant client growth, like AstraZeneca, indicates a promising area for revenue and earnings increases.Analysartikel • Sep 07
Do Paysign's (NASDAQ:PAYS) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysartikel • Aug 02
Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Paysign, Inc. ( NASDAQ:PAYS ) shareholders are probably feeling a little disappointed, since its shares fell 7.1% to...Seeking Alpha • Jun 30
Paysign: Expect Rapid Growth In Its Pharma Business
Summary Shares have risen sharply this year, reflecting solid business performance. Its pharma segment is experiencing exceptional growth and has a long runway for continued expansion. My valuation model indicates that shares have limited upside. Read the full article on Seeking AlphaAnalysartikel • Apr 26
Paysign, Inc. (NASDAQ:PAYS) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Paysign, Inc. ( NASDAQ:PAYS ) shares have continued their recent momentum with a 30% gain in the last month alone. The...Analysartikel • Mar 29
Here's Why We Think PaySign (NASDAQ:PAYS) Is Well Worth Watching
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysartikel • Jan 25
Revenues Tell The Story For PaySign, Inc. (NASDAQ:PAYS)
PaySign, Inc.'s ( NASDAQ:PAYS ) price-to-sales (or "P/S") ratio of 3.4x may not look like an appealing investment...Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$10m |
| Dec 31 2025 | US$3m | US$1m | US$8m |
| Sep 30 2025 | n/a | n/a | US$8m |
| Jun 30 2025 | n/a | n/a | US$7m |
| Mar 31 2025 | n/a | n/a | US$6m |
| Dec 31 2024 | US$1m | US$1m | US$4m |
| Sep 30 2024 | n/a | n/a | US$8m |
| Jun 30 2024 | n/a | n/a | US$8m |
| Mar 31 2024 | n/a | n/a | US$7m |
| Dec 31 2023 | US$1m | US$950k | US$6m |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | US$1m |
| Mar 31 2023 | n/a | n/a | US$1m |
| Dec 31 2022 | US$3m | US$950k | US$1m |
| Sep 30 2022 | n/a | n/a | US$420k |
| Jun 30 2022 | n/a | n/a | -US$703k |
| Mar 31 2022 | n/a | n/a | -US$1m |
| Dec 31 2021 | US$963k | US$950k | -US$3m |
| Sep 30 2021 | n/a | n/a | -US$7m |
| Jun 30 2021 | n/a | n/a | -US$13m |
| Mar 31 2021 | n/a | n/a | -US$12m |
| Dec 31 2020 | US$1m | US$950k | -US$9m |
| Sep 30 2020 | n/a | n/a | -US$3m |
| Jun 30 2020 | n/a | n/a | US$6m |
| Mar 31 2020 | n/a | n/a | US$8m |
| Dec 31 2019 | US$1m | US$883k | US$7m |
Ersättning vs marknad: Mark s total kompensation ($USD 2.75M ) är ungefär genomsnittet för företag av liknande storlek på US marknaden ($USD 2.45M ).
Ersättning vs inkomst: Ersättningen för Mark har ökat med mer än 20 % det senaste året.
VD OCH KONCERNCHEF
Mark Newcomer (61 yo)
20.3yrs
Anställning
US$2,754,265
Kompensation
Mr. Mark R. Newcomer co-founded PaySign, Inc., (formerly known as 3Pea International, Inc.) and serves as its President from January 24, 2024, serves as Director since May 8, 2026 and has been its Chief Ex...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Co-Founder | 20.3yrs | US$2.75m | 16.59% $ 79.0m | |
| President of Patient Affordability | 6.1yrs | US$1.54m | 0.045% $ 212.5k | |
| Chief Innovation Officer | 1.3yrs | US$1.49m | 0% $ 0 | |
| CFO & Treasurer | 5.4yrs | US$697.56k | 0.97% $ 4.6m | |
| Chief Operating Officer | 2.5yrs | inga uppgifter | inga uppgifter | |
| Chief Technology Officer | 5yrs | inga uppgifter | inga uppgifter | |
| Chief Compliance Officer | 8.4yrs | inga uppgifter | inga uppgifter | |
| General Counsel | 7.8yrs | US$699.04k | 0.87% $ 4.2m | |
| Executive Vice President of Strategy & Corporate Development | 8.3yrs | inga uppgifter | inga uppgifter | |
| Vice President of Marketing | no data | inga uppgifter | inga uppgifter | |
| Executive VP of EFT Operations & Executive Director | 5.4yrs | inga uppgifter | 1.26% $ 6.0m | |
| Chief Payments Officer & Director | 2.5yrs | inga uppgifter | 0.42% $ 2.0m |
5.4yrs
Genomsnittlig anställningstid
59yo
Genomsnittlig ålder
Erfaren ledning: PAYS s ledningsgrupp är erfaren och erfaren ( 5.4 års genomsnittlig anställning).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Co-Founder | less than a year | US$2.75m | 16.59% $ 79.0m | |
| Executive VP of EFT Operations & Executive Director | 7.7yrs | inga uppgifter | 1.26% $ 6.0m | |
| Chief Payments Officer & Director | 3.9yrs | inga uppgifter | 0.42% $ 2.0m | |
| Independent Chairman of the Board | 8.2yrs | US$164.20k | 0.23% $ 1.1m | |
| Independent Director | 3.6yrs | US$164.20k | 0.089% $ 426.0k | |
| Non-Executive Independent Director | 8.2yrs | US$164.20k | 0.45% $ 2.1m | |
| Member of Advisory Board | 11.8yrs | inga uppgifter | inga uppgifter | |
| Member of Advisory Board | 11.8yrs | inga uppgifter | inga uppgifter | |
| Non-Executive Independent Director | 8.3yrs | US$164.20k | 0.46% $ 2.2m |
8.2yrs
Genomsnittlig anställningstid
69yo
Genomsnittlig ålder
Erfaren styrelse: PAYS s styrelse anses vara erfaren ( 8.2 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/08 11:20 |
| Aktiekurs vid dagens slut | 2026/07/08 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Paysign, Inc. bevakas av 6 analytiker. 5 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Gary Prestopino | Barrington Research Associates, Inc. |
| Austin Moldow | Canaccord Genuity |
| Peter Heckmann | D.A. Davidson & Co. |